This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Mar 1;28(7):1091-6.

doi: 10.1200/JCO.2009.25.8624. Epub 2010 Feb 1.

Whither HER2-related therapeutics?

Pradip De, Brian Leyland-Jones

PMID: 20124168
DOI: 10.1200/JCO.2009.25.8624

Editorial

Whither HER2-related therapeutics?

Pradip De et al. J Clin Oncol. 2010.

. 2010 Mar 1;28(7):1091-6.

doi: 10.1200/JCO.2009.25.8624. Epub 2010 Feb 1.

Authors

Pradip De, Brian Leyland-Jones

PMID: 20124168
DOI: 10.1200/JCO.2009.25.8624

No abstract available

PubMed Disclaimer

Similar articles

Antitumor activity of HER-2 inhibitors.
Rabindran SK. Rabindran SK. Cancer Lett. 2005 Sep 8;227(1):9-23. doi: 10.1016/j.canlet.2004.11.015. Epub 2004 Dec 15. Cancer Lett. 2005. PMID: 16051028 Review.
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A, Vidal L, Shaw H, de Bono J. Reid A, et al. Eur J Cancer. 2007 Feb;43(3):481-9. doi: 10.1016/j.ejca.2006.11.007. Epub 2007 Jan 8. Eur J Cancer. 2007. PMID: 17208435 Review.
Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
Lin JH, Tsai CH, Chu JS, Chen JY, Takada K, Shew JY. Lin JH, et al. J Virol. 2007 Jun;81(11):5705-13. doi: 10.1128/JVI.00076-07. Epub 2007 Mar 21. J Virol. 2007. PMID: 17376931 Free PMC article.
Axonal neuregulin-1 regulates myelin sheath thickness.
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA. Michailov GV, et al. Science. 2004 Apr 30;304(5671):700-3. doi: 10.1126/science.1095862. Epub 2004 Mar 25. Science. 2004. PMID: 15044753
Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y, Yarden Y. Mosesson Y, et al. Semin Cancer Biol. 2004 Aug;14(4):262-70. doi: 10.1016/j.semcancer.2004.04.005. Semin Cancer Biol. 2004. PMID: 15219619 Review.

See all similar articles

Cited by

Chemotherapy-resistant metastatic breast cancer.
Marquette C, Nabell L. Marquette C, et al. Curr Treat Options Oncol. 2012 Jun;13(2):263-75. doi: 10.1007/s11864-012-0184-6. Curr Treat Options Oncol. 2012. PMID: 22528367
Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.
Jay SM, Kurtagic E, Alvarez LM, de Picciotto S, Sanchez E, Hawkins JF, Prince RN, Guerrero Y, Treasure CL, Lee RT, Griffith LG. Jay SM, et al. J Biol Chem. 2011 Aug 5;286(31):27729-40. doi: 10.1074/jbc.M111.221093. Epub 2011 May 26. J Biol Chem. 2011. PMID: 21622572 Free PMC article.
A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey N, Williams C, Leyland-Jones B, De P. Dey N, et al. Am J Transl Res. 2015 Apr 15;7(4):733-50. eCollection 2015. Am J Transl Res. 2015. PMID: 26064441 Free PMC article.
What can molecular pathology contribute to the management of renal cell carcinoma?
Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. Stewart GD, et al. Nat Rev Urol. 2011 May;8(5):255-65. doi: 10.1038/nrurol.2011.43. Epub 2011 Apr 12. Nat Rev Urol. 2011. PMID: 21487387 Review.
Systems pathology.
Faratian D. Faratian D. Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S4. doi: 10.1186/bcr2733. Breast Cancer Res. 2010. PMID: 21172088 Free PMC article. No abstract available.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal